探讨持续泵入美罗培南对脓毒血症多重耐药菌患者的研究  

Study on the Clinical Efficacy of Meropenem Continuous Pumping in Patients with Sepsis with Multidrug Resistant Bacteria

作　　者：吴晓鹏[1] 张彬 张金花[1] 陈桂红 陈辉[3] 张国君[4] Wu Xiaopeng;Zhang Bin;Zhang Jinhua;Chen Guihong;Chen Hui;Zhang Guojun(Department of Pharmacy,Songgang People's Hospital,Baoan District,Shenzhen 518105;Department of Medicine,Baoan District Health Bureau,Shenzhen 518105;Department of Respiratory Medicine,Songgang People's Hospital,Baoan District,Shenzhen 518105;Department of Intensive Medicine,Songgang People's Hospital,Baoan District,Shenzhen 518105)

机构地区：[1]深圳市宝安区松岗人民医院药剂科,深圳518105 [2]深圳市宝安区卫生健康局医政科,深圳518105 [3]深圳市宝安区松岗人民医院呼吸内科,深圳518105 [4]深圳市宝安区松岗人民医院重症医学科,深圳518105

出　　处：《数理医药学杂志》2021年第4期522-524,共3页Journal of Mathematical Medicine

基　　金：深圳市宝安区医疗卫生基础研究项目;项目编号:2019JD270

摘　　要：目的:探究美罗培南持续泵入对脓毒血症多重耐药菌患者的临床疗效研究。方法:2019年9月~2020年12月期间在某院选取符合条件的脓毒血症多重耐药菌患者60例为研究对象,采用随机数字表法随机分为A组和B组各30例。A组采用持续泵入美罗培南治疗,B组给予静脉滴注美罗培南治疗,对比两组患者的临床疗效和两组患者的细菌总清除率。结果:A组治疗前PCT约为(16.25±1.64)ng·ml-1,CRP约为(74.13±22.12)mg·ml-1;A组治疗后PCT约为(0.35±0.11)ng·ml-1,CRP约为(15.25±1.25)mg·ml-1;B组治疗前PCT约为(16.33±1.78)ng·ml-1,CRP约为(73.24±22.36)mg·ml-1,B组治疗后PCT约为(1.17±0.55)ng·ml-1,CRP约为(23.25±11.37)mg·ml-1。由此可见,A组指标比B组降低更多;A组总清除率为93.33%,高于B组66.66%(P<0.05),具有统计学意义;A组患者住院时间为(11.21±1.23)d,B组患者住院时间为(18.56±1.24)d,组间比较,差异具有统计学意义(P<0.05);A组的总体有效率为90.00%,高于B组66.66%(P<0.05),具有统计学意义。结论:对脓毒血症多重耐药菌患者给予持续泵入美罗培南治疗,既可以取得显著的临床效果,提高细菌清除率,又可以减少患者住院时间,对于临床治疗有着重要意义,值得应用和推荐。Objective:To explore the clinical efficacy of meropenem continuous pumping in patients with sepsis with multidrug resistant bacteria.Methods:From September 2019 to December 2020,60 sepsis patients with multidrug resistant bacteria were selected as the research objects and randomly divided into group A and group B,with 30 cases in each group.Group A was treated with continuous infusion of meropenem,and group B was treated with intravenous drip of meropenem.The clinical efficacy and total bacterial clearance rate of the two groups were compared.Results:Before treatment,PCT and CRP in group A were(16.25±1.64)ng·ml-1 and(74.13±22.12)mg·ml-1 respectively;After treatment,PCT and CRP in group A were(0.35±0.11)ng·ml-1 and(15.25±1.25)mg·ml-1 respectively;Before treatment,PCT and CRP in group B were(16.33±1.78)ng·ml-1 and(73.24±22.36)mg·ml-1 respectively,and after treatment,PCT and CRP in group B were(1.17±0.55)ng·ml-1 and(23.25±11.37)respectively.Thus,the group A was lower than the group B.The total clearance rate of group A was 93.33%,which was higher than 66.66%of group B(P<0.05),with statistical significance;The hospitalization time of group A was(11.21±1.23)d,and that of group B was(18.56±1.24)d,with statistical significance(P<0.05).The overall effective rate of group A was 90.00%,which was higher than 66.66%of group B,with statistical significance(P<0.05).Conclusion:Continuous infusion of meropenem in patients with sepsis with multidrug resistant bacteria can not only achieve significant clinical effect,improve the bacterial clearance rate,but also reduce the length of hospital stay,which is of great significance for clinical treatment,and is worthy of application and recommendation.

关 键 词：美罗培南 脓毒血症 多重耐药菌 临床疗效 

分 类 号：R917[医药卫生—药物分析学]